Back to results
US 2026/0217686 A1Published application
N-Myristoyltransferase Inhibitors And Methods Of Use
AssigneeSeattle Children's Hospital d/b/a Seattle Children's Research Institute
InventorsAlexis Kaushansky, Bart Staker, Rachael Zigweid, Kamalakannan Vijayan, Morten Grøti, Diego Rodriguez-Hernandez
Life of this patent
Estimating the term…
Abstract
Provided herein are compounds of Formula (I), which are useful as N-myristoyltransferase (NMT) inhibitors. Also provided herein are methods of treating, ameliorating, and/or preventing malaria with compounds of Formula (I), including treating dormant forms of malaria known as hypnozoites.
Claims21
A compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof:
- wherein
- A is an optionally fused 6-membered aryl or heteroaryl ring, which is optionally substituted by at least one substituent selected from the group consisting of F, Cl, Br, I, OR, OC(O)N(R)2, CN, NO, NO2, ONO2, CF3, OCF3, R, N(R)2, SR, SOR, SO2R, SO2N(R)2, SO3R, C(O)R, C(O)C(O)R, C(O)CH2C(O)R, C(S)R, C(O)OR, OC(O)R, and C(O)N(R)2;
- X is C, CH, or N, provided that if A is present then X is C;
- Z is CH or N;
- Y is CH or N;
- R1 is selected from the group consisting of hydrogen, F, Cl, and Br;
- L is O, NR, or ═N—*, wherein the bond with * is attached to the aryl ring;
- T is —C1-6 alkyl-C5-6 heteroaryl, wherein the C5-6 heteroaryl is optionally substituted with at least one selected from the group consisting of F, Cl, Br, I, OR, OC(O)N(R)2, CN, NO, NO2, ONO2, CF3, OCF3, R, N(R)2, SR, SOR, SO2R, SO2N(R)2, SO3R, C(O)R, C(O)C(O)R, C(O)CH2C(O)R, C(S)R, C(O)OR, OC(O)R, and C(O)N(R)2;
- V is —C0-6 alkyl-C5-6 heterocyclyl, —O—C0-6 alkyl-C5-6 heterocyclyl, —C0-6 alkyl-NR2, or —O—C2-6 alkyl-NR2, wherein the C5-6 heterocyclyl is optionally substituted with at least one selected from the group consisting of F, Cl, Br, I, OR, OC(O)N(R)2, CN, NO, NO2, ONO2, CF3, OCF3, R, N(R)2, SR, SOR, SO2R, SO2N(R)2, SO3R, C(O)R, C(O)C(O)R, C(O)CH2C(O)R, C(S)R, C(O)OR, OC(O)R, and C(O)N(R)2;
- R is independently at each occurrence selected from the group consisting of hydrogen or optionally substituted C1-12 alkyl;
- R2 is independently at each occurrence selected from the group consisting of F, Cl, Br, I, OR, OC(O)N(R)2, CN, NO, NO2, ONO2, CF3, OCF3, R, N(R)2, SR, SOR, SO2R, SO2N(R)2, SO3R, C(O)R, C(O)C(O)R, C(O)CH2C(O)R, C(S)R, C(O)OR, OC(O)R, and C(O)N(R)2;
- R3 is independently at each occurrence selected from the group consisting of F, Cl, Br, I, OR, OC(O)N(R)2, CN, NO, NO2, ONO2, CF3, OCF3, R, N(R)2, SR, SOR, SO2R, SO2N(R)2, SO3R, C(O)R, C(O)C(O)R, C(O)CH2C(O)R, C(S)R, C(O)OR, OC(O)R, and C(O)N(R)2;
- m is 0, 1, 2, or 3;
- and
- n is 0, 1, 2, 3, or 4.
12 more elements
21-24. (canceled)
Dependencies are inferred from the claim text.